Related Articles
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Heterogeneous methylation of the O6-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)
Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide